CLDX

NASDAQ · Biotechnology

Celldex Therapeutics Inc

Small-Cap Stocks Biotech Stocks Healthcare Stocks

$30.90

+0.87 (+2.90%)

As of Mar 22, 10:07 PM ET ·

CLDX News1 articles

Celldex Shares Pull Back After Barzolvolimab Enrollment Milestone

Celldex Therapeutics shares retreated about 4% in premarket trading Thursday, giving back some of the prior session's 24% surge. The biotech completed patient enrollment for two key Phase 3 studies of its mast cell inhibitor barzolvolimab six months early.